Advanced Gene Editing Method Restores Vision in Mouse Model

#1
1 Like
#2

Meanwhile - bad news on the senolytics research front this week… the latest Unity Biotechnology trial failed to meet the targeted endpoints:

UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm

UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline

https://www.globenewswire.com/news-release/2023/03/27/2634654/0/en/UNITY-Biotechnology-Announces-Results-from-Phase-2-ENVISION-Study-of-UBX1325-in-Patients-with-Wet-Age-Related-Macular-Degeneration.html

2 Likes
#3

UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. In the 24-week data of the Phase 2 BEHOLD study in patients with DME, a single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 24 weeks compared to sham treatment. In a Phase 1 clinical study in advanced wet AMD and DME, UBX1325 showed a favorable safety profile and improvements in visual acuity sustained through 24 weeks following a single intravitreal injection.